Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.968
-0.022 (-2.20%)
Dec 27, 2024, 4:00 PM EST - Market closed

Akari Therapeutics, Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2023FY 2022FY 2021FY 2020FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Selling, General & Admin
9.211.3613.538.089.168.22
Upgrade
Research & Development
8.255.459.569.138.828.74
Upgrade
Operating Expenses
17.4416.8123.0917.2117.9816.96
Upgrade
Operating Income
-17.44-16.81-23.09-17.21-17.98-16.96
Upgrade
Interest Expense
-0.12-----
Upgrade
Interest & Investment Income
0.010.080.050.010.010.01
Upgrade
Currency Exchange Gain (Loss)
0.140.140.45-0.190.35-0.07
Upgrade
Other Non Operating Income (Expenses)
1.266.584.84-0.030.530.18
Upgrade
EBT Excluding Unusual Items
-16.14-10.01-17.75-17.42-17.08-16.85
Upgrade
Pretax Income
-20.16-10.01-17.75-17.42-17.08-16.85
Upgrade
Net Income
-20.16-10.01-17.75-17.42-17.08-16.85
Upgrade
Net Income to Common
-20.16-10.01-17.75-17.42-17.08-16.85
Upgrade
Shares Outstanding (Basic)
853221
Upgrade
Shares Outstanding (Diluted)
853221
Upgrade
Shares Change (YoY)
76.18%56.79%45.46%35.87%72.53%18.87%
Upgrade
EPS (Basic)
-2.46-2.04-5.69-8.12-10.81-18.40
Upgrade
EPS (Diluted)
-2.46-2.04-5.69-8.12-20.00-18.40
Upgrade
Free Cash Flow
-14.84-16.43-21.5-18.85-16.95-12.92
Upgrade
Free Cash Flow Per Share
-1.81-3.36-6.89-8.78-10.73-14.11
Upgrade
EBITDA
-17.43-16.8-23.08-17.21-17.97-16.94
Upgrade
D&A For EBITDA
0.010000.010.02
Upgrade
EBIT
-17.44-16.81-23.09-17.21-17.98-16.96
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.